Current Neurology and Neuroscience Reports

, Volume 10, Issue 2, pp 92–100 | Cite as

Therapeutic Strategies for Diabetic Neuropathy



Diabetes is the leading cause of peripheral neuropathy globally. Duration of diabetes, glycemic control, and preexisting cardiovascular risk factors independently correlate with the development and progression of diabetic peripheral neuropathy as well as cardiovascular autonomic neuropathy. The pathogenesis of diabetic neuropathy remains unclear, although insulin resistance, oxidative stress, mitochondrial dysfunction, abnormal glucose metabolism, advanced glycation end products, neurotrophic factors, and protein kinase C activation all may play a role. Strict glycemic control remains the only available treatment option, although other treatments are in development. Multiple options are available for symptom management. In this article, we review factors associated with development and progression of diabetic neuropathy and discuss available treatment options.


Diabetes Peripheral neuropathy Cardiac autonomic neuropathy Glycemic control Cardiovascular risk factors 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Martyn CN, Hughes RA: Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997, 62:310–318.CrossRefPubMedGoogle Scholar
  2. 2.
    Abbott CA, Carrington AL, Ashe H, et al.: The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002, 19:377–384.CrossRefPubMedGoogle Scholar
  3. 3.
    Beiswenger KK, Calcutt NA, Mizisin AP: Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008, 110:351–362.CrossRefPubMedGoogle Scholar
  4. 4.
    Dyck PJ, Kratz KM, Karnes JL, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817–824.PubMedGoogle Scholar
  5. 5.
    Dyck PJ, Davies JL, Wilson DM, et al.: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999, 22:1479–1486.CrossRefPubMedGoogle Scholar
  6. 6.
    The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995, 122:561–568.Google Scholar
  7. 7.
    Martin CL, Albers J, Herman WH, et al.: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006, 29:340–344.CrossRefPubMedGoogle Scholar
  8. 8.
    Tesfaye S, Chaturvedi N, Eaton SE, et al.: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341–350.CrossRefPubMedGoogle Scholar
  9. 9.
    Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995, 38:869–880.Google Scholar
  10. 10.
    Franklin GM, Kahn LB, Baxter J, et al.: Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990, 131:633–643.PubMedGoogle Scholar
  11. 11.
    Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448–1453.CrossRefPubMedGoogle Scholar
  12. 12.
    Sumner CJ, Sheth S, Griffin JW, et al.: The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108–111.PubMedGoogle Scholar
  13. 13.
    Dyck PJ, Klein CJ, Weigand SD: Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007, 36:536–541.CrossRefPubMedGoogle Scholar
  14. 14.
    Barr EL, Wong TY, Tapp RJ, et al.: Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999–2000 AusDiab. Diabetes Care 2006, 29:1114–1116.CrossRefPubMedGoogle Scholar
  15. 15.
    Forrest KY, Maser RE, Pambianco G, et al.: Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997, 46:665–670.CrossRefPubMedGoogle Scholar
  16. 16.••
    Elliott J, Tesfaye S, Chaturvedi N, et al.: Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009, 32:1896–1900. This study evaluated risk factors for the development of diabetic neuropathy in a large, prospectively evaluated cohort (EuroDiab Prospective Complications Study) and described the significant association between cardiovascular risk factors and neuropathy, independent of glycemic control. These factors require further intensive study and likely will prove to be important in controlling and treating diabetic neuropathy.Google Scholar
  17. 17.
    Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993, 16:1446–1452.CrossRefPubMedGoogle Scholar
  18. 18.
    Mitchell BD, Hawthorne VM, Vinik AI: Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990, 13:434–437.CrossRefPubMedGoogle Scholar
  19. 19.
    Maser RE, Steenkiste AR, Dorman JS, et al.: Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989, 38:1456–1461.Google Scholar
  20. 20.
    Wiggin TD, Sullivan KA, Pop-Busui R, et al.: Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634–1640.CrossRefPubMedGoogle Scholar
  21. 21.
    Maser RE, Pfeifer MA, Dorman JS, et al.: Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990, 150:1218–1222.CrossRefPubMedGoogle Scholar
  22. 22.
    Valensi P, Sachs RN, Harfouche B, et al.: Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001, 24:339–343.CrossRefPubMedGoogle Scholar
  23. 23.
    Maser RE, Mitchell BD, Vinik AI, Freeman R: The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003, 26:1895–1901.CrossRefPubMedGoogle Scholar
  24. 24.
    Kempler P, Tesfaye S, Chaturvedi N, et al.: Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002, 19:900–909.CrossRefPubMedGoogle Scholar
  25. 25.
    The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998, 41:416–423.Google Scholar
  26. 26.
    Witte DR, Tesfaye S, Chaturvedi N, et al.: Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164–171.CrossRefPubMedGoogle Scholar
  27. 27.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–986.Google Scholar
  28. 28.•
    Albers JW, Herman WH, Pop-Busui R, et al.: Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007, 30:2613–2618. This study highlights the impact of strict glycemic control on nerve injury even in patients without clinical or electrophysiologic evidence of neuropathy.Google Scholar
  29. 29.
    Pop-Busui R, Low PA, Waberski BH, et al.: Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886–2893.CrossRefPubMedGoogle Scholar
  30. 30.
    Dyck PJ, Davies JL, Clark VM, et al.: Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 2006, 29:2282–2288.CrossRefPubMedGoogle Scholar
  31. 31.•
    Oates PJ: Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008, 9:14–36. This recent article reviews the evidence supporting a role for the aldose reductase pathway in the pathogenesis of diabetic neuropathy and the potential for aldose reductase inhibition as a therapeutic option.Google Scholar
  32. 32.
    Heesom AE, Millward A, Demaine AG: Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998, 64:213–216.CrossRefPubMedGoogle Scholar
  33. 33.
    Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999, 53:580–591.Google Scholar
  34. 34.
    Gabbay KH: Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Curr Diab Rep 2004, 4:405–408.CrossRefPubMedGoogle Scholar
  35. 35.
    Goto Y, Hotta N, Shigeta Y, et al.: Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995, 49:269–277.Google Scholar
  36. 36.
    Bril V, Buchanan RA: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006, 29:68–72.CrossRefPubMedGoogle Scholar
  37. 37.
    Hotta N, Toyota T, Matsuoka K, et al.: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001, 24:1776–1782.CrossRefPubMedGoogle Scholar
  38. 38.
    Bril V, Hirose T, Tomioka S, Buchanan R: Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009, 32:1256–1260.CrossRefPubMedGoogle Scholar
  39. 39.
    Apfel SC, Schwartz S, Adornato BT, et al.: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000, 284:2215–2221.Google Scholar
  40. 40.
    Apfel SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002, 50:393–413.CrossRefPubMedGoogle Scholar
  41. 41.
    Simovic D, Isner JM, Ropper AH, et al.: Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001, 58:761–768.CrossRefPubMedGoogle Scholar
  42. 42.
    Murakami T, Arai M, Sunada Y, Nakamura A: VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. J Gene Med 2006, 8:773–781.CrossRefPubMedGoogle Scholar
  43. 43.
    Carmeliet P, Storkebaum E: Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002, 13:39–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Ropper AH, Gorson KC, Gooch CL, et al.: Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009, 65:386–393.CrossRefPubMedGoogle Scholar
  45. 45.
    Freeman R, Durso-Decruz E, Emir B: Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008, 31:1448–1454.CrossRefPubMedGoogle Scholar
  46. 46.
    Kajdasz DK, Iyengar S, Desaiah D, et al.: Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007, 29 Suppl:2536–2546.Google Scholar
  47. 47.
    Wernicke JF, Pritchett YL, D’Souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411–1420.CrossRefPubMedGoogle Scholar
  48. 48.
    Tesfaye S: Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009, 3:136–143.CrossRefPubMedGoogle Scholar
  49. 49.
    Rauck RL, Shaibani A, Biton V, et al.: Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23:150–158.CrossRefPubMedGoogle Scholar
  50. 50.
    Wymer JP, Simpson J, Sen D, Bongardt S: Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009, 25:376–385.CrossRefPubMedGoogle Scholar
  51. 51.
    Baron R, Mayoral V, Leijon G, et al.: 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009, 25:1663–1676.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.The Neurological InstituteColumbia UniversityNew YorkUSA

Personalised recommendations